IXICO plc (IXI.L)

GBp 11.75

(0.0%)

Market Cap (In GBp)

10.88 Million

Revenue (In GBp)

6.66 Million

Net Income (In GBp)

-1.17 Million

Avg. Volume

34.77 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.35-14.6
PE
-
EPS
-
Beta Value
0.747
ISIN
GB00BFXR4C20
CUSIP
G4988H111
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Bram Goorden M.Sc.
Employee Count
-
Website
https://ixico.com
Ipo Date
1996-04-25
Details
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.